Overview

Longitudinal Antimalarial Combinations in Uganda

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare different ways of treating uncomplicated malaria in a group of Ugandan children. The study will be divided into 2 parts. Part 1 of the study will consist of 600 children, ages 1-10, living in the Mulago III Parish of Kampala. Approximately 90 children living in the same household as children from the Phase 1 portion of the study will be enrolled in Phase II of this study. Participants in Phase II of the study will receive an insecticide treated net to cover their bed. Over the course of the study, participants will be tested for malaria when they present to the clinic with a fever or illness. Participants that test positive for malaria will be given 1 of 3 possible study drug combinations. Study procedures will include physical exams and blood samples. Children will participate for about 3 years. Protocol 05-0110 is a study related to this protocol.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Amodiaquine
Amodiaquine, artesunate drug combination
Antimalarials
Artemether
Artemether-lumefantrine combination
Artemether, Lumefantrine Drug Combination
Artemisinins
Artesunate
Lumefantrine
Pyrimethamine
Sulfadoxine